News | November 01, 2022
Aptar Pharma completes Phase I global injectables expansion program
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
India will become a digital health leader, as we have the world’s best technical manpower required and our data is the cheapest in the world, approaching 100 percent coverage
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
He also encouraged all G20 members to contribute their public keys to the proposed Global Federated Public Trust Directory for ensuring seamless worldwide mobility of people and goods
Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Results reinforce commitment to next-generation oral SERD development programme
Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.
CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
Subscribe To Our Newsletter & Stay Updated
